Pharvaris To Present New Data On Hereditary Angioedema Treatment At Upcoming Conferences

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:

 

American College of Allergy, Asthma, & Immunology's Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation:

• Poster: Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study
  
  Speaker: John Anderson, M.D.
  
  Format: e-Poster (R102)
  
  Date, Time: Friday, Oct. 25, 2:00-2:15 p.m. EDT
  
  Location: Monitor 21, Exhibit Hall A
• Poster: Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results
  
  Speaker: John Anderson, M.D.
  
  Format: e-Poster (R103)
  
  Date, Time: Friday, Oct. 25, 2:15-2:30 p.m. EDT
  
  Location: Monitor 21, Exhibit Hall A
• Poster: Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders
  
  Speaker: Evangelia Pardali, Ph.D.
  
  Format: e-Poster (R088)
  
  Date, Time: Friday, Oct. 25, 2:30-2:45 p.m. EDT
  
  Location: Monitor 20, Exhibit Hall A
• Poster: Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders
  
  Speaker: Evangelia Pardali, Ph.D.
  
  Format: e-Poster (R090)
  
  Date, Time: Friday, Oct. 25, 3:00-3:15 p.m. EDT
  
  Location: Monitor 20, Exhibit Hall A
• Poster: The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans
  
  Speaker: Juan Bravo, Ph.D.
  
  Format: e-Poster (R112)
  
  Date, Time: Friday, Oct. 25, 4:30-4:45 p.m. EDT
  
  Location: Monitor 21, Exhibit Hall A
• Poster: CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis
  
  Speaker: H. James Wedner, M.D.
  
  Format: e-Poster (R100)
  
  Date, time: Friday, Oct. 25, 5:30-5:45 p.m. EDT
  
  Location: Monitor 20, Exhibit Hall A
• Poster: Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life
  
  Speaker: H. James Wedner, M.D.
  
  Format: e-Poster (R101)
  
  Date, Time: Friday, Oct. 25, 5:45-6:00 p.m. EDT
  
  Location: Monitor 20, Exhibit Hall A
  
   

Canadian Society of Allergy and Clinical Immunology (CSACI), Banff, Alberta, Canada, November 6-9, 2024. Three abstracts have been accepted for poster presentation.

• Poster: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 Trial
  
  Speaker: William H. Yang, M.D., FRCPC, FAAAAI
  
  Format: Poster
  
  Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
• Poster: Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results
  
  Speaker: William H. Yang, M.D., FRCPC, FAAAAI
  
  Format: Poster
  
  Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
• Poster: Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results 
  
  Speaker: Hugo Chapdelaine, M.D., FRCPC
  
  Format: Poster
  
  Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)

Japanese Society of Allergology (JSA), Kyoto, Japan, October 18-20, 2024. One abstract has been accepted for oral presentation.

• Presentation: Efficacy and safety of oral deucrictibant IR capsule in HAE: RAPIDe-3 phase 3 trial design
  
  Speaker: Prof. Michihiro Hide, M.D., Ph.D.
  
  Format: Oral Presentation
  
  Date, Time: Sunday, Oct. 20, 13:30-14:45 JST (12:30 -1:45 a.m. EDT)